PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Reports Year End 2023 Financial Results and Provides Business Update
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
Cognition Announces Closing of $11.5 Million Public Offering of Common Stock
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
Cognition Announces Pricing of $11.5 Million Public Offering of Common Stock
Cognition Therapeutics Presents Analyses at AD/PD 2024
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders,...